SRRK Scholar Rock Holding Corp
Company Analysis
Latest News
🟢 Scholar Rock is trading 4.25% up today with biotech sector up 2.10%
Scholar Rock is trading at $43.12, up 4.25%, with the biotech sector’s 2.10% gain the clearest available context. - No major new company-specific announcement...
🔴 Scholar Rock is trading 4.49% down in pre-market as biotech ETF XBI falls 3.65% pre-market
Scholar Rock is trading at $38.11, down 4.49%, with biotech-sector pressure the more likely context; no clear company-specific catalyst surfaced for October...
🟢 Scholar Rock is trading 4.02% up today amid a broader biotech rally
Scholar Rock is trading at $41.19, up 4.02%, alongside a broader biotech rally; however, no direct cause for the move is established. - No clear Scholar...
Scholar Rock Resubmits European SMA Application With Alternate Fill-Finish Facility
Scholar Rock has resubmitted its Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for apitegromab to treat spinal muscular...
🟢 Scholar Rock is trading 4.83% up in pre-market
Scholar Rock is trading at $44.50, up 4.83% before the October 7, 2026 session; the reason for the move remains unclear. - Searches found no clear new...
🔴 Scholar Rock is trading 4.17% down with no clear catalyst identified
Scholar Rock is trading 4.17% lower at $44.86, with no clear catalyst identified in available sources. - Available October 5 reporting did not identify a new...
🔴 Scholar Rock is trading 4.3% down
Scholar Rock is trading at $46.23, down 4.33%, with no clear company-specific catalyst identified for the October 1 decline. - No clear company-specific...
🟢 Scholar Rock is trading 4.45% up today after JPMorgan raised its price target to $70
Scholar Rock is trading 4.45% higher at $50.30 after JPMorgan raised its price target to $70 from $63 while maintaining an Overweight rating on September...
🟢 Scholar Rock is trading 5.2% up today on broader market strength
Scholar Rock is trading $49.09, up +5.22%, as broader risk appetite supports equities. • The move reflects an opening-week recovery in a broadly stronger...
🔴 Scholar Rock is trading 4% down today after post-approval profit-taking
Scholar Rock is trading 4% down at $47.05 as investors reassess valuation following the FDA approval of ISEMBYLD. - Barclays downgraded the shares to...
Scholar Rock's Credibility Takes a Hit After Management Botched FDA Details — Can Investors Trust the Story Now?
Shares of Scholar Rock plunged 10% to $46.64 on September 15, extending a bruising two-day slide that has erased roughly 19% of the stock's value since...
🔴 Scholar Rock is trading 10% down today after FDA requires pregnancy-safety study
Scholar Rock is trading 10% down at $46.64 after clarifying that FDA approval of ISEMBYLD includes post-marketing safety commitments. - Management had...
Scholar Rock Clarifies FDA Post-Marketing Safety Requirements for Drug ISEMBYLD™
Scholar Rock Holding Corporation issued a clarification regarding post-marketing requirements for its newly FDA-approved spinal muscular atrophy (SMA) drug,...
🔴 Scholar Rock is trading 8.1% down today after Barclays downgraded shares to Equal Weight
Scholar Rock is trading 8.1% down at $47.65 after Barclays downgraded the shares to Equal Weight from Overweight. - Barclays raised its price target to $58...
🔴 Scholar Rock is trading 4.3% down today after shares rallied sharply in extended trading
Scholar Rock is trading 4.3% down now at $53.04 after shares rallied sharply in extended trading following Friday’s FDA approval of ISEMBYLD, its first...
Scholar Rock Announces FDA Approval for ISEMBYLD™, a Muscle-Targeted SMA Treatment
Scholar Rock Holding Corporation announced that the U.S. Food and Drug Administration (FDA) has approved ISEMBYLD™ (apitegromab-mstn) for the treatment of...
🟢 Scholar Rock is trading 11.89% up in pre-market after FDA approval of ISEMBYLD
Scholar Rock is trading 11.89% up in pre-market at $62.00 after the FDA approved ISEMBYLD on September 11, 2026, the company’s first approved treatment. - It...
🟢 Scholar Rock is trading 8.21% up in pre-market after FDA approves ISEMBYLD
Scholar Rock is trading 8.21% up at $59.96 after the FDA approved ISEMBYLD on September 11, 2026, the company’s first approved treatment for spinal muscular...
Scholar Rock Lands Its First FDA Approval — But Can a $7 Billion Company With Zero Revenue Justify the Price Tag?
Shares of Scholar Rock surged +13.5% to $62.91 after the FDA cleared Isembyld, its muscle-strengthening treatment for spinal muscular atrophy, vaulting the...
🟢 Scholar Rock is trading 13.5% up in after-hours trading after first FDA approval for SMA therapy
Scholar Rock is trading at $62.91 (+13.54%) after the FDA approved its spinal muscular atrophy therapy on September 11, 2026, marking its first regulatory...